CAR-T Cell Therapy: Who Is It Right For? (2026 Update)

CAR-T cell therapy is considered for some blood cancer patients who have relapsed or stopped responding to multiple standard treatments. It is not used as an initial treatment at the time of first diagnosis.

Key Takeaways

• CAR-T is a cell therapy in which a patient's own T cells are engineered with an artificial receptor that recognizes cancer cells, then infused back into the body (National Cancer Center Korea).
• Candidates are mainly patients with certain relapsed or refractory blood cancers — B-cell lymphoma, acute lymphoblastic leukemia, and multiple myeloma — while use in solid tumors remains investigational.
• The hallmark side effects, cytokine release syndrome (CRS) and neurologic toxicity (ICANS), can appear anywhere from a few days to two weeks after infusion, which is why CAR-T is only given at hospitals with dedicated management systems in place.
• The full process — cell collection, manufacturing, preconditioning, infusion, and observation — often requires a stay of two months or longer.
• Whether transplant or CAR-T should come first depends on the type of disease, prior treatment history, and donor availability, and is determined by the treating medical team.

Which Blood Cancers and Conditions Warrant CAR-T Consideration?

• CAR-T is considered for patients who have already received standard treatment but relapsed or did not respond — it is not a first-line treatment given at initial diagnosis.
• Typical candidates include B-cell lymphomas such as relapsed or refractory diffuse large B-cell lymphoma, acute lymphoblastic leukemia in children and young adults, and multiple myeloma after multiple prior lines of treatment.
• Eligibility is determined by subtype, the type and number of prior treatments received, overall performance status, heart/lung/kidney function, presence of active infection, and whether there is central nervous system involvement. CAR-T is not yet standard treatment for solid tumors; for these cases, the focus is on checking eligibility for clinical trial participation.

What Is the Treatment Sequence?

• Step 1, T-cell collection — blood is circulated through a machine to collect T cells; this procedure takes several hours and does not require anesthesia.
• Step 2, cell manufacturing — the collected cells are sent to a manufacturing facility to produce CAR-T cells, which typically takes several weeks; during this time, interim treatment is often given to keep the disease from progressing.
• Step 3, preconditioning chemotherapy — given a few days before infusion to reduce lymphocytes and make room for the new cells to engraft.
• Step 4, infusion — the CAR-T cells are infused intravenously, and in principle this is done only once.
• Step 5, observation — patients are typically hospitalized for about two weeks to monitor for side effects, and after discharge, they stay near the hospital for a further period with frequent outpatient visits.

How Are Side Effects Managed?

• Cytokine release syndrome occurs when the immune response activates all at once, causing high fever, chills, low blood pressure, and low oxygen levels; it can range from mild fever to a severe condition requiring intensive care.
• Neurologic toxicity can present as slurred speech, inability to write, or confusion. Because caregivers often notice these symptoms before patients do, it is standard practice for a companion to stay with the patient throughout the observation period.
• Both conditions have established medications and protocols for management, so prompt reporting while staying close to the hospital is essential. In addition, a period of reduced blood cell counts and lowered immunoglobulin levels increases infection risk, which may require prophylactic antibiotics and immunoglobulin replacement.

FAQ — Which Should Come First, Transplant or CAR-T?

The order depends on the type of disease, prior treatment history, donor availability, and the current state of the disease. The results of evaluating both options are summarized in a written opinion, and the final sequence is decided in consultation with the treating medical team.

FAQ — Can CAR-T Be Received in Korea?

CAR-T cell therapy has been introduced in Korea and is administered in the hematology departments of tertiary hospitals equipped with cell collection and intensive care response systems. Which products are approved for which indications changes over time, so eligibility is confirmed during the remote review (pre-arrival review) stage. For overseas patients, procedures for cell manufacturing, import/export, and hospital-specific acceptance conditions can vary, making advance confirmation especially important.

Sources and Notes

• This article was written based on notes on blood cancer and CAR-T cell therapy (National Cancer Center Korea, NCCN Patient Guidelines, National Cancer Registration Statistics 2019–2023).
• This content is provided for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on individual condition. Please consult with your medical team to determine an accurate diagnosis and treatment plan.